Drugs / ADM03820
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04592549 | Dec 2020 → Oct 2023 | COVID-19 | Alachua Government Services, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05142527 | Jan 2023 → Jan 2024 | COVID-19 | Alachua Government Services, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADM03820 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05142527 ↗ |
| Modality | Monoclonal antibody | “Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19” NCT04592549 ↗ |
| Route | Intramuscular | “ADM03820 administered as IM injections” NCT04592549 ↗ |